Cardiac F-18 FDG PET
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
PET/CT Evaluation of Cardiac Sarcoidosis
PET/CT Evaluation of Cardiac Sarcoidosis John P. Bois, MDa,*, Daniele Muser, MDb,1, Panithaya Chareonthaitawee, MDa KEYWORDS Cardiac sarcoidosis Positron emission tomography Fluorine-18 deoxyglucose KEY POINTS Sarcoidosis can involve the heart at with resultant significant morbidity and mortality. PET/CT is the most accurate method by which to diagnose cardiac sarcoidosis. Patient preparation prior to the PET/CT cardiac sarcoid study is critical to ensure diagnostic images are obtained. PET/CT detection of both active inflammation and scar has diagnostic, prognostic, and therapeutic importance. Ongoing areas of research include the use of PET to quantify the extent of myocardial inflammation and the discrepancies in myocardial blood flow in the cardiac sarcoidosis population. INTRODUCTION experiencing spontaneous remission and the remaining one-third developing either a stable or The increasing implementation of advanced car- progressive course.3 diovascular imaging in the form of cardiac PET/ The rate of cardiac involvement by sarcoidosis, CT has had a significant impact on the manage- otherwise termed CS, is variable and ranges ment of cardiac sarcoidosis (CS), one that con- from 20% to 75%.4,5 Furthermore, CS accounts tinues to evolve. Sarcoidosis is characterized for one-fourth of sarcoid-related mortality in the histologically by the presence of noncaseating United States and upward of 85% of death attrib- granulomas, with a predilection for the pulmonary uted to sarcoidosis in the Japanese population.4,6 system but with the ability to involve nearly every The high rate of involvement of the cardiovascular organ. Although the development of sarcoidosis system by sarcoidosis coupled with the potential is believed the sequelae of an exaggerated im- lethal outcomes has rendered accurate and timely mune or inflammatory response to an inciting in- diagnosis of this disease entity as imperative to fectious or environmental trigger, the specific patient care. -
Dobutamine-Induced Contractile Reserve in Stunned, Hibernating, and Scarred Myocardium in Patients with Ischemic Cardiomyopathy
CLINICAL INVESTIGATIONS Dobutamine-Induced Contractile Reserve in Stunned, Hibernating, and Scarred Myocardium in Patients with Ischemic Cardiomyopathy Arend F.L. Schinkel, MD, PhD1; Jeroen J. Bax, MD, PhD2; Ron van Domburg, PhD1; Abdou Elhendy, MD, PhD1; Roelf Valkema, MD, PhD3; Eleni C. Vourvouri, MD, PhD1; Fabiola B. Sozzi, MD, PhD1; Jos R.T.C. Roelandt, MD, PhD1; and Don Poldermans, MD, PhD1 1Thoraxcenter, Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands; 2Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; and 3Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands Because of damage to cardiomyocytes and the contractile appa- In patients with ischemic cardiomyopathy, distinguishing ratus, contractile reserve may be observed less frequently in hi- between hibernating, stunned, and scarred myocardium may bernating than in stunned myocardium. The aim of this study was have important implications for clinical management and to assess the presence of contractile reserve in response to do- butamine infusion in a large group of patients with stunned and outcome. If hibernating or stunned myocardium is present, hibernating myocardium. Methods: A total of 198 consecutive coronary revascularization may not only reverse regional patients with ischemic cardiomyopathy (left ventricular ejection wall motion abnormalities but also improve global function, fraction Յ 40%) underwent resting 2-dimensional echocardiogra- heart failure symptoms, and survival (1–3). Hibernating phy to assess regional contractile dysfunction. On the basis of myocardium has been defined as a chronic state of contrac- assessment of perfusion (with 99mTc-tetrofosmin SPECT) and glu- tile dysfunction with reduced blood flow at rest (4,5). Fre- 18 cose use (with F-FDG SPECT), dysfunctional segments were quently, however, regional perfusion in chronic dysfunc- grouped. -
Positron Emission Tomography and Myocardial Imaging
Heart 2000;83:475–480 (generally a cyclotron).1 Production of isotopes IMAGING TECHNIQUES with the shortest half lives has to be carried out in the vicinity of the scanner and necessitates the installation of cyclotron and radiochemis- Positron emission tomography and try facilities. However, 18F compounds can be delivered from a relatively remote site of myocardial imaging production. The commercial success of PET has been driven by 18F labelled fluorodeoxyglu- 475 Paolo G Camici cose (FDG) which is used to measure glucose MRC Cyclotron Unit, Imperial College School of Medicine, metabolism in tissues. Because of the longer Hammersmith Hospital, London, UK half life of 18F (table 1), many centres rely on production from a centralised cyclotron, thus avoiding the expense of individual facilities. maging with positron emission tomography However, research centres aiming to derive (PET) oVers unrivalled sensitivity and spe- most from the power of PET require on site Icificity for research into biochemical path- production of a range of tracers. ways and pharmacological mechanisms in vivo. Cardiac and neurological research with PET Positron emission and detection has flourished over the past 20 years, but it is Positrons are emitted with a continuous range only more recently that cardiology has begun to of energies up to a maximum, which is charac- benefit from the advantages provided by PET. teristic of each particular isotope (table 1). The From the physical point of view, scanning of positron is successively slowed down by the heart presents a challenge because of Coulomb interaction with atomic electrons greater complications in correcting for photon and “annihilates” with an electron when its attenuation and scattered radiation, and be- energy has been reduced close to zero, resulting cause of movement of the heart and lungs. -
Myocardial Perfusion Imaging with PET
SPECIAL CONTRIBUTION Myocardial Perfusion Imaging with PET Markus Schwaiger Nuklearmedizinische Klinik und Poliklini/çDer Technischen Universitdt Munchen, Klini/wm Rechts der Isar, Munich, Germany SPEC!' (5). PET spatial resolution is superior to that of AlthoughSPECThas become an acceptedimagingtechnique SPECT, resulting in superior image quality and less partial formyocardialperfusionstudies,thereare severaladvantages volume effect (5). Most PET images are processed with a to evaluatingcoronaryarterydisease (CAD)withPET.CADis a spatial resolution of about 6—10mm, as compared with complex, dynamic disease and quantitativemeasurements of 10—15mm for SPECF image reconstruction. myocardialbloodflowby PET can improvethe fUnCtiOnalchar The majoradvantageof PET is its ability to correct for acterizationof CAD.The majoradvantage of PET over SPECT attenuation.Traditionalmyocardialperfusionimagingwith is @rtsabilityto provideattenuation-correctedimages, whichde single-photon radiotracers such as 201'flposes significant creases incidenceof attenuation artifactsand increases spea challenges in avoiding or identifying and correcting for flcfty.Myocardialpertusion imagingwithPET can also provide moreaccurateinformationon localizationofdisease, as wellas attenuation artifacts, particularly those that involve the quantitativeassessment, inabsolutevalues, ofmyocardialblood inferior wall in male patients and the anterior wall in female flow.The measurement ofregionalflowreserve allowsforphys patients (6,7). iologiccharacterizationof stenosis severity, -
Time-Of-Flight PET Map out Goals by Joel S
Volume 3, Issue 4 FALL 2006 pet center of excellence newsletter PET COE Board Meets with Industry Advisory Group to Time-of-Flight PET Map Out Goals By Joel S. Karp, PhD he idea to use time-of-flight (TOF) information in PET image reconstruction By James W. Fletcher, MD Twas originally proposed in the 1960s at a very early stage in the development of President, PET Center of Excellence positron imaging. By the early 1980s, fully functional TOF PET systems had been built, An inaugural meet- not long after the first conventional PET systems were completed. Why then did it take ing was held recently so long to introduce a clinical TOF PET scanner, and how does it compare to the first in Chicago between the TOF PET instruments built 25 years ago? PET Center of Excel- Time-of-Flight Theory lence Board of Directors The concept of time-of-flight means simply that for each annihilation event, we note (BOD) and the Industry the precise time that each of the coincident photons is detected and calculate the dif- Advisory Group (IAG). ference. Since the closer photon will arrive at its detector first, the difference in arrival The meeting was very times helps pin down the location of the annihilation event along the line between the James W. Fletcher well attended with rep- two detectors. resentation from a large To understand why this information is useful, we need to recall that normally in cross-section of industry. PET we collect line pair data at many angles and create tomographic images through The interaction and discussion at the con- traditional filtered back-projection or through an iterative series of back- and forward- joint morning meeting was lively and infor- projection steps. -
Noninvasive Characterization of Stunned, Hibernating, Remodeled and Nonviable Myocardium in Ischemic Cardiomyopathy Jagat Narula, MD, PHD, FACC, Martin S
Journal of the American College of Cardiology Vol. 36, No. 6, 2000 © 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00959-1 Cardiomyopathy Noninvasive Characterization of Stunned, Hibernating, Remodeled and Nonviable Myocardium in Ischemic Cardiomyopathy Jagat Narula, MD, PHD, FACC, Martin S. Dawson, MD, Binoy K. Singh, MD, Aman Amanullah, MD, Elmo R. Acio, MD, Farooq A. Chaudhry, MD, FACC, Ramin B. Arani, PHD, Ami E. Iskandrian, MD, FACC Philadelphia, Pennsylvania OBJECTIVES We evaluated a novel protocol of dual-isotope, gated single-photon emission computed tomographic (SPECT) imaging combined with low and high dose dobutamine as a single test for the characterization of various types of altered myocardial dysfunction. BACKGROUND Myocardial perfusion tomography and echocardiography have been used separately for the assessment of myocardial viability. However, it is possible to assess perfusion, function and contractile reserve using gated SPECT imaging. METHODS We studied 54 patients with ischemic cardiomyopathy using rest and 4 h redistribution thallium-201 imaging and dobutamine technetium-99m sestamibi SPECT imaging. The sestamibi images were acquired 1 h after infusion of the maximal tolerated dose of dobutamine and again during infusion of dobutamine at a low dose to estimate contractile reserve. Myocardial segments were defined as hibernating, stunned, remodeled or scarred. RESULTS Severe regional dysfunction was present in 584 (54%) of 1,080 segments. Based on the combination of function and perfusion characteristics in these 584 segments, 24% (n ϭ 140) were labeled as hibernating; 23% (n ϭ 136) as stunned; 30% (n ϭ 177) as remodeled; and 22% (n ϭ 131) as scarred. -
Atrium Health Delineation of Privileges Specialty of Radiology
ATRIUM HEALTH DELINEATION OF PRIVILEGES SPECIALTY OF RADIOLOGY Print Name YES NO** I have participated in direct patient care in the hospital setting within the past two (2) years. **If the answer is No, please do not complete this form. Contact the Medical Staff Office at (704) 355-2147 for additional instructions regarding the required proctoring process. Initial appointment Reappointment Updated DOP Request for Clinical Privileges To be eligible for core privileges in Radiology, the applicant must meet the following qualifications: If the applicant is not currently certified in Radiology by the American Board of Medical Specialties (ABMS) or the American Osteopathic Association (AOA) the applicant must: 1. Provide documentation of successful completion of an ACGME or AOA accredited Radiology training program, within the past five (5) years; AND 2. Provide documentation of the performance and interpretation of at least five-thousand (5,000) imaging tests in the past two (2) years. Applicants have the burden of producing information deemed adequate by the hospital for proper evaluation of current competence, and other qualifications and for resolving any doubts; OR If the applicant is currently certified in Radiology by the American Board of Medical Specialties (ABMS) or the American Osteopathic Association (AOA), the applicant must: 1. Provide documentation of general pediatric certification from the American Board of Medical Specialties or the American Osteopathic Association (AOA); AND 2. Provide documentation of the performance and interpretation of at least five-thousand (5,000) imaging tests in the past two (2) years. Applicants have the burden of producing information deemed adequate by the hospital for proper evaluation of current competence, and other qualifications and for resolving any doubts. -
Cardiac Radiology)
CAE002-b F-18 FDG PET/CT and MRI In the Diagnosis and Management of Cardiac Sarcoidosis Education Exhibits Location: CA Community, Learning Center Participants Richard Anthony R. Coulden MD (Presenter): Nothing to Disclose Emer Sonnex : Nothing to Disclose Hefin Jones FRCR : Nothing to Disclose Indrajeet Das MBBCh, MRCP : Nothing to Disclose Jonathan Thomas Abele MD : Nothing to Disclose TEACHING POINTS In patients with established non-cardiac sarcoidosis, both FDG PET/CT and cardiac MRI can be used to diagnose cardiac involvement. We will learn how and why: 1. FDG PET/CT identifies active disease and can be used in both diagnosis and management. Serial PET allows assessment of response to immunosuppressive treatment. 2. Cardiac MRI identifies myocardial edema and scar. It has proven value in diagnosis but its role in monitoring disease in response to treatment is unclear. 3. Cardiac MRI provides additional value in assessment of ventricular volumes and function and maybe a helpful surrogate in monitoring treatment response. 4. FDG PET/CT and MRI are complementary techniques. TABLE OF CONTENTS/OUTLINE 1. Criteria for clinical diagnosis of cardiac sarcoidosis (Japanese Ministry of Health and Welfare) 2. How to use FDG PET/CT for inflammatory cardiac imaging 3. How to use cardiac MRI for infiltrative cardiomyopathies 4. Relative roles of Cardiac MRI and FDG PET/CT in: a. the imaging diagnosis of cardiac sarcoidosis b. follow-up of disease activity and response to immunosuppressive treatment. CAE004-b Dynamic Myocardial Perfusion Imaging by 3rd Generation Dual-Source CT Education Exhibits Location: CA Community, Learning Center Participants Marisa Marjolein Lubbers MD (Presenter): Nothing to Disclose Adriaan Coenen MD : Nothing to Disclose Akira Kurata : Nothing to Disclose Marcel L. -
Evicore Cardiac Imaging Guidelines
CLINICAL GUIDELINES Cardiac Imaging Policy Version 1.0 Effective February 14, 2020 eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight. CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein. © 2019 eviCore healthcare. All rights reserved. Cardiac Imaging Guidelines V1.0 Cardiac Imaging Guidelines Abbreviations for Cardiac Imaging Guidelines 3 Glossary 4 CD-1: General Guidelines 5 CD-2: Echocardiography (ECHO) 15 CD-3: Nuclear Cardiac Imaging 26 CD-4: Cardiac CT, Coronary CTA, and CT for Coronary Calcium (CAC) 33 CD-5: Cardiac MRI 40 CD-6: Cardiac PET 45 CD-7: Diagnostic Heart Catheterization 49 CD-8: Pulmonary Artery and Vein Imaging 56 CD-9: Congestive Heart Failure 59 CD-10: Cardiac Trauma 62 CD-11: Adult Congenital Heart Disease 64 CD-12: Cancer Therapeutics-Related -
Myocardial Perfusion Imaging Versus CT Coronary Angiography: When to Use Which?
CONTINUING EDUCATION Myocardial Perfusion Imaging Versus CT Coronary Angiography: When to Use Which? Balaji Tamarappoo and Rory Hachamovitch Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the various types of noninvasive cardiac imaging tests and how the results of each are utilized; (2) recent advances in CT coronary angiography, PET myocardial perfusion imaging, and SPECT myocardial perfusion imaging of coronary artery disease; and (3) the clinical use of anatomic versus physiologic tests in symptomatic patients with known or suspected coronary artery disease. Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNM designates each JNM continuing education article for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, participants can access this activity through the SNM Web site (http://www.snm.org/ce_online) through June 2012. suspected coronary artery disease (CAD). The results of Both anatomy- and physiology-based approaches to patient these tests are used for patient risk stratification, evaluation management have advantages and limitations. Compared of myocardial ischemia as a cause of symptoms, and assess- with the latter, the former has a superior ability to exclude ment of ongoing disease management. Stress myocardial disease and does not miss high-risk coronary artery disease (CAD). -
Pet/Ct) Imaging
The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields. The American College of Radiology will periodically define new practice parameters and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice parameters and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each practice parameter and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review and approval. The practice parameters and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized. Adopted 2017 (Resolution 26)* ACR–SPR–STR PRACTICE PARAMETER FOR THE PERFORMANCE OF CARDIAC POSITRON EMISSION TOMOGRAPHY - COMPUTED TOMOGRAPHY (PET/CT) IMAGING PREAMBLE This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care1. -
2009 Appropriate Use Critera for Cardiac Radionuclide Imaging
Appropriate Use Criteria for Cardiac Radionuclide Imaging Ratings Moderator 1 2 3 4 5 6 7 8 9 101112131415 Indication Median MADM R Agree Table 1. Detection of CAD: Symptomatic Evaluation of Ischemic Equivalent (Non-Acute) 1 • Low pre-test probability of CAD 4 2 1 5 1 3 4 2 1 5 3 2 4 3 3 3 1.1 I • ECG interpretable AND able to exercise 2 • Low pre-test probability of CAD 9 7 3 9 5 7 6 7 7 8 8 8 7 7 5 7 1.1 A + • ECG uninterpretable OR unable to exercise 3 • Intermediate pre-test probability of CAD 9 728173788877 7 7 7 1.4 A + • ECG interpretable AND able to exercise 4 • Intermediate pre-test probability of CAD 9 9 8 9 7 8 9 9 99 9 9 9 9 9 9 0.3 A + • ECG uninterpretable OR unable to exercise 5 • High pre-test probability of CAD 9 9 59 5 8 6 8 7 5 8 7 6 8 9 8 1.3 A • Regardless of ECG interpretability and ability to exercise Acute Chest Pain 6 • Possible ACS 9 9 8 8 7 8 7 8 3 8 7 8 7 8 6 8 0.9 A + • ECG—no ischemic changes or with LBBB or electronically paced ventricular rhythm • Low-Risk TIMI Score • Peak Troponin: borderline, equivocal, minimally elevated 7 • Possible ACS 9 8 1 9 2 8 5 8 1 7 7 7 5 8 9 7 2.1 A • ECG—no ischemic changes or with LBBB or electronically paced ventricular rhythm • High-Risk TIMI Score • Peak Troponin: borderline, equivocal, minimally elevated 8 • Possible ACS 9 8 9 9 3 7 3 8 8 8 7 8 8 7 4 8 1.3 A + • ECG—no ischemic changes or with LBBB or electronically paced ventricular rhythm • Low-Risk TIMI Score • Negative troponin levels 9 • Possible ACS 9 9 8 9 7 5 7 9 1 8 6 7 8 8 8 8 1.3 A + • ECG—no ischemic changes or with LBBB or electronically paced ventricular rhythm • High-Risk TIMI Score • Negative troponin levels 10 • Definite ACS 111312111111122 1 0.3 I + Acute Chest Pain (Rest Imaging Only) 11 • Possible ACS 9 9 7 7 7 2 68 9 2 8 6 8 8 6 7 1.5 A • ECG—no ischemic changes or with LBBB or electronically paced ventricular rhythm • Initial troponin negative • Recent or on-going chest pain Table 2.